Boston Scientific Invests $1.5B in MiRus, Secures Option to Acquire Its TAVR Technology

Why It Matters

The partnership gives Boston Scientific a fast‑track entry into a next‑generation TAVR market while addressing the gap left by its discontinued valve line, potentially reshaping competition and improving patient outcomes.

Key Takeaways

• Boston Scientific invests $1.5B for 34% stake in MiRus.
• Option to acquire Siegel TAVR tech for total $3B pending milestones.
• Siegel valve shows zero deaths, strokes, pacemaker implants in 30‑day trial.
• Boston Scientific exited its own TAVR line in 2025, shifting focus.
• STAR trial will enroll up to 1,025 patients to validate Siegel valve.

Pulse Analysis

Boston Scientific’s $1.5 billion infusion into MiRus marks a decisive shift in the competitive landscape of transcatheter aortic valve replacement (TAVR). After the company halted sales of its Acurate neo2 and Prime systems in 2025 due to regulatory setbacks, the partnership offers an immediate pathway back into the high‑growth structural‑heart market. By securing a 34% equity position and an exclusive option to acquire the Siegel valve for up to $3 billion, Boston Scientific can leverage MiRus’s proprietary rhenium‑based alloy—free of nickel and cobalt—to differentiate its product line and address unmet clinical needs.

The Siegel valve’s early performance data bolster confidence in its commercial potential. In a July 2025 case series of 15 patients, the device delivered a mean gradient of 6.3 mmHg and a valve area of 2.8 cm², with no incidences of death, stroke, rehospitalization, vascular complications, or permanent pacemaker implantation. Such outcomes suggest a lower risk profile compared with existing platforms, which could translate into higher adoption rates among interventional cardiologists seeking to minimize procedural complications. The upcoming STAR trial, slated to enroll up to 1,025 patients across multiple centers, will provide the robust evidence needed to satisfy FDA and payer requirements.

Strategically, the deal positions Boston Scientific to capture a larger share of the projected $12 billion global TAVR market by 2030. The option to acquire additional structural‑heart assets from MiRus further expands its pipeline, potentially enabling cross‑selling opportunities and economies of scale in manufacturing. For investors and clinicians alike, the collaboration signals a renewed focus on innovation and patient‑centric solutions, reinforcing Boston Scientific’s role as a leading player in cardiovascular device therapy.

Deal Summary

Boston Scientific has invested $1.5 billion in Georgia‑based medtech company MiRus, acquiring a roughly 34% equity stake and an exclusive option to fully purchase MiRus’s Siegel TAVR technology for up to $3 billion pending regulatory milestones. The strategic investment bolsters Boston Scientific’s structural‑heart portfolio after it discontinued its own TAVR valves.